SUPPLEMENTARY DATA

Gene specific effects on brain volume and cognition of *TMEM106B* in frontotemporal lobar degeneration

Marijne Vandebergh^{1,2}, Eliana Marisa Ramos³, Nick Corriveau-Lecavalier^{4,5}, Vijay K Ramana⁴, John Kornak⁶, Carly Mester⁷, Tyler Kolander⁴, Danielle Brushaber⁷, Adam M Staffaroni⁸, Daniel Geschwind⁹, Amy Wolf⁸, Kejal Kantarci⁴, Tania F Gendron¹⁰, Leonard Petrucelli¹⁰, Marleen Van den Broeck^{1,2}, Sarah Wynants^{1,2}, Matthew C Baker¹⁰, Sergi Borrego – Écija¹¹, Brian Appleby¹², Sami Barmada¹³, Andrea Bozoki¹⁴, David Clark¹⁵, R Ryan Darby¹⁶, Bradford C Dickerson¹², Kimiko Domoto-Reilly¹⁷, Julie A. Fields¹⁸, Douglas R. Galasko¹⁹, Nupur Ghoshal²⁰, Neill Graff-Radford¹⁰, Ian M Grant²¹, Lawrence S Honig²², Ging-Yuek Robin Hsiung²³, Edward D Huey²⁴, David Irwin²⁵, David S Knopman⁵, Justin Y Kwan²⁶, Gabriel C Léger¹⁹, Irene Litvan¹⁹, Joseph C Masdeu²⁷, Mario F Mendez³, Chiadi Onyike²⁸, Belen Pascual²⁷, Peter Pressman²⁹, Aaron Ritter³⁰, Erik D Roberson³¹, Allison Snyder²⁶, Anna Campbell Sullivan³², M Carmela Tartaglia³³, Dylan Wint³⁰, Hilary W Heuer⁸, Leah K Forsberg⁵, Adam L Boxer⁸, Howard J Rosen⁸, Bradley F Boeve⁴, Rosa Rademakers^{1,2,10*} on behalf of the ALLFTD Consortium

1 VIB Center for Molecular Neurology, VIB, Antwerp, Belgium

2 Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium

3 Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA

4 Department of Neurology, Mayo Clinic, Rochester, MN, USA

5 Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.

6 Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA

7 Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA

8 Department of Neurology, Memory and Aging Center, University of California, San Francisco Weill Institute for Neurosciences San Francisco California USA.

9 Institute for Precision Health, Departments of Neurology, Psychiatry and Human Genetics at David Geffen School of Medicine, UCLA, Los Angeles CA USA

10 Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA

11 Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Fundació Clínic per a la Recerca Biomèdica, Universitat de Barcelona, Barcelona, Spain 12 Department of Neurology, Case Western Reserve University, Cleveland, OH, USA

13 Department of Neurology, University of Michigan, Ann Arbor, MI, USA

14 Department of Neurology, University of North Carolina, Chapel Hill, NC, USA

15 Department of Neurology, Indiana University, Indianapolis, IN, USA

16 Department of Neurology, Vanderbilt University, Nashville, TN, USA

17 Department of Neurology, University of Washington, Seattle, WA, USA

18 Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA

19 Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA

20 Departments of Neurology and Psychiatry, Washington University School of Medicine, Washington University, St. Louis, MO, USA

21 Department of Psychiatry and Behavioral Sciences, Northwestern Feinberg School of Medicine, Chicago, IL, USA

22 Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, NY, USA; Department of Neurology, Columbia University, New York, NY, USA

23 Division of Neurology, University of British Columbia, Vancouver, British Columbia, Canada

24 Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, Rhode Island, USA

25 Department of Neurology and Penn Frontotemporal Degeneration Center, Perelman School of Medicine, University of Pennsylvania

26 National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA

27 Department of Neurology, Houston Methodist, Houston, TX, USA

28 Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, USA

29 Department of Neurology, University of Colorado, Aurora, CO, USA

30 Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, 89106, USA

31 Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA

32 Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, UT Health San Antonio

33 Tanz Centre for Research in Neurodegenerative Diseases, Division of Neurology, University of Toronto, Toronto, Ontario, Canada *Corresponding author:

Rosa Rademakers, Ph.D. (ORCID: 0000-0002-4049-0863)

VIB Center for Molecular Neurology

Universiteitsplein 1, 2610 Wilrijk, Belgium

Phone: +32 3 265 95 95

E-mail: rosa.rademakers@uantwerpen.vib.be

eTable 1. Individual regions of interest (ROIs) for gray matter volumes. Left and right hemispheres were considered separately in analyses

Cortical volumes	Subcortical volumes	Cerebellar volume
Frontal lobe	Hippocampus	
Temporal lobe	Amygdala	
Parietal lobe	Caudate	
Occipital lobe	Accumbens	Cerebellum
Cingulate cortices: rostral anterior,	Pallidum	
caudal anterior, isthmus, posterior	Thalamus	
Insular cortices	Putamen	

Characteristic	All mutation carriers	C9orf72+	GRN+	MAPT+	Non-carriers
Sample size	373	169	82	106	585
Age at visit (yr), mean (s.d)	51.19 (14.14)	51.18 (13.97)	57.63 (13.25)	46.7 (12.57)	58.59 (13.79)
Female, n (%)	203 (54.42 %)	92 (54.44 %)	40 (48.78 %)	62 (58.49 %)	299 (51.11 %)
Education (yr), mean (s.d)	15.67 (2.48)	15.75 (2.39)	15.72 (2.75)	15.54 (2.48)	15.95 (2.50)
Race, n					
EUR	361	167	79	101	544
Non-EUR	11	1	3	5	34
Unknown	1	1	0	0	7
<i>TMEM106B</i> rs1990622, n					
A/A	161	71	42	42	204
A/G	161	71	36	50	277
G/G	51	27	4	14	104
CDR®+NACC-FTLD Global, n					
0	191	92	44	47	235
0.5	71	38	11	19	83

eTable 2. Demographic characteristics for participants included in the analyses with gray matter volume as outcome (N = 958)

≥ 1	111	39	27	40	267
CDR®+NACC-FTLD sum of boxes, mean (s.d)	3.22 (5.11)	2.52 (4.40)	3.82 (5.65)	3.93 (5.70)	4.03 (4.88)
Primary clinical phenotype, n					
Clinically normal	188	91	42	48	234
MBI/MCI	41	19	8	14	32
bvFTD	91	35	15	38	122
ALS	6	6	0	0	0
FTD-ALS	5	4	0	0	5
PPA	0	3	9	0	87
CBS	3	0	2	1	49
PSP	3	0	1	2	56
Other	21	11	5	3	0
MaCA many (add)	24.42 (6.29)	25.29 (5.22)	22.8 (7.87)	24.09 (6.71)	22.81 (6.91)
MoCA, mean (s.d.)	NA: 31	NA: 15	NA: 7	NA: 7	NA: 54
Total gray matter volume (% of total intracranial volume) mean (s.d)	41.91 (5.62)	41.69 (5.36)	40.68 (5.79)	42.87 (5.66)	41.70 (6.91)

Characteristic	All mutation carriers	C9orf72+	GRN+	MAPT+	Non-carriers
Sample size	465	229	101	113	1116
Age at visit (yr), mean (s.d)	53.17 (14.24)	53.05 (14.19)	58.39 (12.97)	48.44 (12.87)	62.1 (12.47)
Female, n (%)	248 (53.33 %)	126 (55.02 %)	46 (45.54 %)	65 (57.52 %)	527 (47.22 %)
Education (yr), mean (s.d)	15.55 (2.51)	15.62 (2.39)	15.5 (2.89)	15.62 (2.42)	16.06 (2.61)
Race, n					
EUR	448	225	95	108	1021
Non-EUR	13	1	5	5	79
Unknown	4	3	1	0	16
<i>TMEM106B</i> rs1990622, n					
A/A	192	90	49	44	348
A/G	212	108	46	53	551
G/G	61	31	6	16	217
CDR®+NACC-FTLD Global, n					
0	208	108	43	47	279
0.5	78	41	14	20	181

eTable 3. Demographic characteristics for participants included in the analyses with UDS3-EF as outcome (N =1581)

≥ 1	179	80	44	46	656
CDR®+NACC-FTLD sum of boxes, mean (s.d)	4.08 (5.35)	3.78 (5.33)	4.93 (5.96)	3.89 (4.71)	5.27 (4.90)
Primary clinical phenotype, n					
Clinically normal	202	106	42	46	277
MBI/MCI	46	22	9	14	56
bvFTD	144	65	28	44	285
ALS	10	10	0	0	0
FTD-ALS	11	10	0	0	19
PPA	15	3	8	1	204
CBS	9	1	6	1	108
PSP	4	2	1	1	167
Other	24	10	7	6	0
	22.66 (7.49)	23.39 (6.93)	20.8 (8.42)	22.76 (7.53)	21.09 (7.18)
MoCA, mean (s.d.)	NA: 21	NA: 13	NA: 4	NA: 4	NA: 60
USD3-EF (composite z-score) mean (s.d)	-0.65 (1.49)	-0.59 (1.42)	-0.97 (1.52)	-0.49 (1.60)	-1.29 (1.38)

eTable 4. Number of individuals grouped by gene-affection status, included in the fitted linear mixed models to investigate the association between the gene-affection status on the outcome measures

Group	Description	GM volume N=942	UDS3-EF N = 1559	ALSFRS-R N = 1003	UPDRS N = 1087
1	Non-carrier & asymptomatic	234	277	/	/
2	Non-carrier & symptomatic	351	839	746	838
3	GRN & asymptomatic	42	42	/	/
4	GRN & symptomatic	40	59	64	59
5	C9orf72 & asymptomatic	91	106	/	/
6	C9orf72 & symptomatic	78	123	121	119
7	MAPT & asymptomatic	48	46	/	/
8	MAPT & symptomatic	58	67	72	71

eTable 5. Linear mixed models were fitted to investigate the association between the gene-affection status on the gray matter and cognitive (UDS3-EF) outcome measures, adjusted for education, age, sex and CDR+NACC-FTLD sum of boxes score as fixed effects and pedigree as random effect.

	Total gray matter volume		UDS3-EF		
	N = 94	12	N = 1559		
	Coeff (95% CI)	P value	Coeff (95% CI)	P value	
Non-mutation & symptomatic	-1.11 (-1.84,-0.37)	0.003	-1.27 (-1.42,-1.12)	< 2 × 10 ⁻¹⁶	
GRN & presymptomatic	-0.65 (-1.74,0.44)	0.245	-0.07 (-0.34, 0.21)	0.632	
GRN & symptomatic	-3.07 (-4.33,-1.89)	$8.98 imes 10^{-7}$	-1.22 (-1.47, -0.96)	$< 2 imes 10^{-16}$	
C9 & presymptomatic	-1.99 (-2.80,-1.19)	$1.68 imes 10^{-6}$	-0.06 (-0.25, 0.12)	0.510	
C9 & symptomatic	-3.49 (-4.40,-2.58)	1.77 × 10 ⁻¹³	-0.98 (-1.17, -0.78)	$< 2 imes 10^{-16}$	
MAPT & presymptomatic	-0.68 (-1.71,0.35)	0.199	0.19 (-0.07, 0.45)	0.158	
MAPT & symptomatic	-2.71 (-3.77,-1.68)	$4.72 imes 10^{-7}$	-1.04 (-1.27, -0.80)	$< 2 imes 10^{-16}$	
Education	0.07 (-0.01,0.16)	0.110	0.06 (0.04, 0.07)	$1.15 imes 10^{-11}$	
Age at visit	-0.18 (-0.20,-0.16)	< 2 × 10 ⁻¹⁶	-0.02 (-0.02, -0.01)	$< 2 imes 10^{-16}$	
Sex (female)	1.75 (1.32,2.16)	2.14×10^{-15}	-0.10 (-0.19, -0.02)	0.021	
CDR+NACC-FTLD SB	-0.39 (-0.44,-0.33)	< 2 × 10 ⁻¹⁶	-0.11 (-0.13, -0.10)	< 2 × 10 ⁻¹⁶	

eTable 6. Linear mixed models were fitted with education, age, sex, genetic status (non-carrier vs carrier) and the CDR+NACC-FTLD sum of boxes as fixed effects and pedigree as random effect to investigate the association between *TMEM106B* rs1990622 and the outcome measures total gray matter volume and UDS3-EF.

	Total gray matter volume $(N = 958)$		<i>UDS3-EF (N = 1581)</i>	
	Coeff (95% CI)	P value	Coeff (95% CI)	P value
TMEM106B Additive	-0.08 (-0.39,0.22)	0.602	-0.04 (-0.10, 0.03)	0.291
TMEM106B Recessive	-0.20 (-0.78,0.37)	0.489	-0.05 (-0.17,0.07)	0.457

eTable 7. Linear mixed models were fitted with education, age, sex, genetic status (non-carrier vs carrier) and the CDR+NACC-FTLD sum of boxes as fixed effects and pedigree as random effect to investigate the association between *TMEM106B* rs1990622 and the outcome measures total gray matter volume and UDS3-EF in affected individuals

	Total gray matter w	olume	UDS3-EF		
	N = 536		N = 1113	}	
	Coeff (95% CI) P value		Coeff (95% CI)	P value	
TMEM106B			0.04	0.338	
Additive	0.01 (-0.44, 0.47)	0.596	(-0.05, 0.13)		
TMEM106B	0.05 (0.80, 0.70)	0.010	0.04	0.500	
Recessive	-0.03 (-0.89, 0.79)	0.910	(-0.11, 0.20)	0.390	

eTable 8. Linear mixed model statistics for *TMEM106B* rs1990622 on individual gray matter regions of interest in *GRN* carriers with p < 0.05 in the recessive model, after controlling for years of education, sex, age at visit, and CDR+NACC-FTLD SB as fixed effects and pedigree as random effect.

	Coeff (95% CI)	P value
Left thalamus	0.03 (0.01,0.06)	0.006
Right cerebellum	0.24 (0.04,0.43)	0.020
Left cerebellum	0.23 (0.02,0.43)	0.035
Left rostral anterior cingulate	0.011 (0.0007,0.02)	0.040
Right thalamus	0.03 (0.001,0.05)	0.044

eTable 9. Linear mixed model statistics for *TMEM106B* rs1990622 on individual gray matter regions of interest in presymptomatic *GRN* carriers with p < 0.05 in the recessive model, after controlling for years of education, sex and age at visit as fixed effects and pedigree as random effect

	Coeff (95% CI)	P value
Left thalamus	0.03 (0.01,0.05)	0.003
Right cerebellum	0.26 (0.08,0.44)	0.008
Right insular cortex	0.02 (0.008,0.04)	0.008
Left temporal cortex	0.17 (0.04,0.30)	0.013
Right frontal cortex	0.25 (0.07,0.44)	0.014
Right temporal cortex	0.15 (0.03,0.28)	0.024
Left frontal cortex	0.24 (0.04,0.43)	0.025
Right thalamus	0.03 (0.004,0.05)	0.029
Left cerebellum	0.26 (0.03,0.49)	0.032

eTable 10. Longitudinal linear mixed statistics for the association of *TMEM106B* rs1990622 with UDS-3 in presymptomatic *C9orf72* carriers

	Additive		Recessive		
	Coeff (95% CI)	P value	Coeff (95% CI)	P value	
TMEM106B rs1990622	0.22 (0.05, 0.39)	0.014	0.45 (0.13, 0.78)	0.008	
Time since baseline	0.06 (0.0001, 0.12)	0.06	0.06 (-0.001, 0.12)	0.07	
Education	0.05 (-0.003, 0.11)	0.06	0.05 (-0.003, 0.11)	0.05	
Sex (female)	-0.003 (-0.25, 0.25)	0.98	-0.03 (-0.27, 0.22)	0.82	
Age at baseline	-0.02 (-0.03, -0.01)	0.0003	-0.02 (-0.03, -0.10)	0.0003	